vistagen.com (VTGN): יחס חוב להיוון בספרים

Vistagen Therapeutics (VTGN) is accelerating anxiety treatment trials through clinic alliances, while the debt-to-equity chart on GURU.Markets shows a metric fixed at 0.03. The company is implementing nasal sprays that bypass the bloodstream to eliminate side effects. Further growth is based on the results of Phase 3 trials and strict control of cash reserves.

Investors assess the operational strength of assets through the debt-to-equity ratio. For Vistagen Therapeutics (VTGN) in the defensive neuropsychiatric sector, financial stability depends on clinical success rather than market cycles. The debt-to-capitalization ratio reflects the proportion of leverage within the financing structure. Low leverage minimizes bankruptcy risks during prolonged drug trials, confirming the high resilience of the company's business model.